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Abstract
Background: Minimal change disease (MCD) is a common cause of the nephrotic syndrome in adults with limited
evidence on its treatment and prognosis. We examined the presenting characteristics, treatments, and outcomes of
adult patients with MCD in our centre.
Methods: This was an observational cohort study using retrospectively-collected data. All patients who had a renal
biopsy reported as MCD between 1996 and 2012 were included, and data were collected at baseline and during
follow-up. Statistical analysis included Cox-regression analysis to examine which factors were associated with risk of
relapse.
Results: Seventy-eight patients were included, and had a median age of 36 years, and were 60% male and 73%
white. Median follow-up time was 72 months. 37% were in AKI at presentation, which was significantly associated
with a lower serum albumin and older age. Although 10% were steroid-resistant, 98% achieved remission at a
median time of 5 weeks. 61% relapsed, at a median time of 11 months, and patients had a median number of 2
relapses during follow-up. A higher eGFR was associated with an increased risk of relapse (hazard ratio 1.18 [1.03–1.
36] per 10 mL/min increase in eGFR), and females were significantly more likely than males to have an early relapse.
Nearly half of the cohort required an additional immunosuppressive agent on top of glucocorticoids, the most
commonly used being calcineurin inhibitors. Five patients subsequently developed FSGS: these patients had a
lower baseline creatinine, a higher serum albumin, a longer time to remission, and were more likely to be steroid-
resistant. Follow-up renal function was generally preserved, but follow-up creatinine was higher in those who had
presented with AKI, and in those who had been commenced on a RAS inhibitor after biopsy. Infection requiring
admission, diabetes mellitus and venous thromboembolism developed in 14%, 12%, and 12% of patients
respectively.
Conclusions: Nearly all adults with MCD achieve remission, but relapses and disease- and therapy-related
complications are common. In our cohort, eGFR and gender were associated with risk of relapse, and these
previously undescribed associations could be explored further in future work.
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Background
Minimal change disease (MCD) refers to the occurrence
of the nephrotic syndrome (NS) with a renal biopsy show-
ing normal glomeruli on light microscopy, no staining on
immunofluorescence microscopy, and diffuse foot process
effacement on electron microscopy [1]. It accounts for ap-
proximately 11–16% of NS in adults and is the third com-
monest cause after membranous nephropathy and focal
segmental glomerulosclerosis (FSGS) [1–4].
Historically, untreated MCD was associated with a
slow rate of spontaneous remission, and with
life-threatening complications of NS including sepsis
and thrombosis. MCD is therefore usually treated with
immunosuppression, the cornerstone being glucocorti-
coids. A 2008 Cochrane review identified only three ran-
domised controlled trials (RCT) examining the first-line
treatment of MCD in adults, and these had small num-
bers of participants and inadequate power to detect dif-
ferences in therapeutic efficacy [5]. The review was also
unable to identify any RCT data for the treatment of re-
lapsing or steroid-resistant disease [5]. Guidelines for
the treatment of adult MCD are therefore based largely
on extrapolation from RCTs in children and observa-
tional studies.
Although there are several published case series of pa-
tients with adult MCD, there are relatively few studies
on the treatment and outcomes of adults with MCD [6–
13]. We collected data on the baseline characteristics,
treatments, and outcomes of adult patients with MCD
in our UK renal centre.
Methods
This was an observational cohort study using
retrospectively-collected data. The cohort comprised
adults in our renal centre with MCD, who were identi-
fied by a search of our pathology database for all renal
biopsies performed between 1996 and 2012 which were
reported as MCD. Patients with multiple biopsies were
included in the dataset only once. Demographic, clinical,
and laboratory data were collected from the hospital
electronic database and clinic letters, and baseline la-
boratory data were the closest available to the time of
renal biopsy within seven days. Outcome data were col-
lected up to December 2013, and patients lost to
follow-up were censored at the point of their last clinic
visit.
Estimated glomerular filtration rate (eGFR) was calcu-
lated using the four-variable Modification of Diet in
Renal Disease (MDRD) study equation [14]. Proteinuria
was measured using a urine albumin:creatinine ratio
(uACR) or a 24-h urine collection, and sometimes dur-
ing follow-up a urine dipstick for the determination of
remission or relapse. Haematuria was defined as ≥45 red
blood cells/μL on flow cytometry of a mid-stream urine
specimen (the upper limit of the reference range in our
centre). Acute kidney injury (AKI) was defined as a rise
in serum creatinine of ≥50% known or presumed to have
occurred in the preceding seven days, and episodes of
AKI were staged 1–3 by serum creatinine as per the Kid-
ney Disease Improving Global Outcomes (KDIGO) AKI
guideline [15].
Complete remission (CR) was defined as a uACR <
30 mg/mmol or a urine dipstick negative for protein. In
patients who attained CR, a relapse was defined as a
uACR > 220 mg/mmol or an increase in proteinuria suf-
ficient for the managing clinician to alter medical ther-
apy. Steroid-resistance was defined as persistent
proteinuria despite high-dose prednisolone sufficient for
the managing clinician to introduce an additional im-
munosuppressive agent. Steroid-dependence was defined
as a relapse while the patient was on tapering steroid
therapy, or within two weeks of completing steroid ther-
apy. Frequently relapsing disease was defined as three or
more relapses in a year.
Statistical analyses were performed using IBM SPSS
Statistics for Macintosh, Version 22 (Armonk, NY: IBM
Corp, 2013). Complete case analysis was used. Categor-
ical variables are expressed as a number and percentage,
and continuous variables are expressed as a mean and
standard deviation (SD) or median and interquartile
range (IQR). Differences between continuous variables
were tested for statistical significance using Student’s
t-test or, for non-parametric analyses, the
Mann-Whitney U test or Kruskal-Wallis test depending
on the number of groups being compared. Due to sam-
ple size considerations, exact methods were used for the
analysis of categorical variables (Fisher’s exact test or an
exact chi-square test computed using the Monte Carlo
method). Kaplan-Meier plots were generated to show
time to CR and time to relapse, and Cox regression ana-
lysis was used to assess the associations between base-
line characteristics and time to CR and time to relapse.
Statistical significance was taken to be a P value < 0.05.>
Results
Seventy-eight patients had a renal biopsy consistent with
MCD between 1996 and 2012 and were followed up for a
median time of 72 months (range 6–190). Demographic,
clinical, and laboratory data from the time of renal biopsy
are shown in Table 1. Six (8%) patients were suspected of
having secondary MCD, with the underlying cause being
chronic lymphocytic leukaemia in one patient, Kimura
disease in one patient, and drug-related in four patients
(three due to non-steroidal anti-inflammatory drugs, and
one due to either tiopronin or captopril). Twenty-one
(27%) patients had a history of NS in childhood.
The cohort included 17 patients who already had a diag-
nosis of MCD, and were biopsied either in the context of
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relapsing disease or to check for evidence of calcineurin
inhibitor (CNI) toxicity. The other 61 patients were all
presenting for the first time, presumably nephrotic, al-
though only 52 patients had available proteinuria data to
confirm NS.
Patients with their first presentation of MCD
The baseline characteristics of the 52 patients presenting
for the first time with NS are shown separately in Table
1. At presentation, 19 (37%) patients had AKI (16 of
these had imaging specifically of the renal veins, none of
whom had evidence of thrombosis). Those with AKI
were older (53 vs 40 years, P = 0.028), and had a lower
serum albumin (19 vs 23 g/L, P = 0.032). There was no
statistically significant association between having AKI
at presentation and level of proteinuria, the presence of
haematuria, gender, or ethnicity.
Initial therapy and response
Of the 52 patients who were presenting with NS for the
first time, one entered CR spontaneously before taking
any immunosuppression. The other 51 patients (includ-
ing the six with suspected secondary MCD) all received
daily oral prednisolone: most patients (36 [72%]) re-
ceived 60 mg (range 30–60, median 60). Initial tapering
prednisolone therapy was continued for a median total
duration of 6 (IQR 4–12) months.
Forty-six (90%) patients were steroid-responsive, i.e.
attained CR with prednisolone only. The other five (10%)
patients were judged steroid-resistant by the treating clin-
ician and commenced an additional immunosuppressive
agent after 3 weeks in two patients, 14 weeks in one pa-
tient, and 17 weeks in two patients. Three patients re-
ceived a CNI (two achieved CR, at 1 week and 26 weeks;
the third patient never achieved CR and underwent a re-
peat biopsy which showed FSGS), and two received cyclo-
phosphamide (both achieved CR, at 4 weeks and
14 weeks).
Overall, 51 (98%) of 52 patients attained CR. Figure 1
shows the cumulative proportion of the cohort who
Table 1 Baseline characteristics of the study population
Characteristic Whole cohort (N = 78) Subgroup:
first presentation (N = 52)
Completeness
of data (%)
Age (years) 36 (25–50) 47 (31–63) 100
Gender (male) 47 (60) 30 (58) 100
Ethnicity 99
White 56 (73) 40 (77)
South Asian 14 (18) 6 (11)
Black 6 (8) 5 (10)
Other 1 (1) 1 (2)
Serum creatinine (μmol/L)a 91 (70–122) 105 (78–138) 100
Estimated GFR (mL/min/1.73m2)a 82 (57–106) 68 (46–92) 100
Acute kidney injury 22 (28) 19 (37) 100
Proteinuria 82
ACR (mg/mmol) (N = 51) 594 (458–899) 609 (505–913)
24 h collection (g/24 h) (N = 13) 5.0 (4.0–8.3) 4.5 (3.4–8.2)
Serum albumin (g/L) 22 (17–30) 21 (17–24) 97
Serum cholesterol (mmol/L) 9.0 (7.3–12.1) 9.0 (7.4–12.4) 83
Haematuria 9 (15) 4 (10) 80
Baseline characteristics of the whole study population and of the subgroup of patients biopsied during their first presentation with nephrotic syndrome.
Continuous variables are expressed as a median (interquartile range) and categorical variables as a number (percentage). MCD minimal change disease; GFR
glomerular filtration rate, estimated by 4-variable MDRD equation; ACR albumin-to-creatinine ratio. aIncludes patients with acute kidney injury
Fig. 1 Kaplan-Meier plot showing the cumulative proportion
achieving complete remission from the time of commencing
initial therapy
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achieved CR from the time of commencing initial ther-
apy. Median time to CR was 5 (IQR 2–11) weeks, and
the number (percentage) who attained CR were 22
(42%) by 4 weeks, 34 (65%) by 8 weeks, 39 (75%) by
12 weeks, and 41 (79%) by 16 weeks.
The associations between baseline characteristics and
time to CR are shown in Table 2. There were no signifi-
cant associations between any of the examined baseline
variables and time to CR. Consistent with this, early re-
sponders (CR within 6 weeks, 29 patients) and late re-
sponders (CR after 6 weeks, 19 patients), had no
significant differences with regards to age, gender, ethni-
city, serum creatinine, AKI at presentation, serum albu-
min, level of proteinuria, serum cholesterol, or presence
of haematuria.
Relapses
Thirty-one patients (61% of those patients who had
achieved CR) relapsed, including 22 (43%) patients who
had multiple relapses. Figure 2 shows the cumulative pro-
portion of the cohort who had relapsed from the time of
attaining CR. By six months, 17 (33%) patients had re-
lapsed, including 11 who were steroid-dependent, and me-
dian time to relapse was 11 months. Throughout
follow-up, patients had a median of two relapses (IQR 0–4,
range 0–11), and ten (13%) patients had frequently relaps-
ing disease.
The single patient who had spontaneously entered CR
never relapsed. Of the 46 steroid-responsive patients, 28
(61%) relapsed. All 28 patients were put back on
high-dose prednisolone and all re-attained remission. Of
Table 2 Associations between patient characteristics and time to remission and relapse by Cox-regression analysis
Characteristic Remission Relapse
HR (95% CI) P HR (95% CI) P
Age (years)a 0.97 (0.83–1.12) 0.64 0.81 (0.64–1.01) 0.06
Gender 0.62 0.32
Male 1 1
Female 0.86 (0.49–1.54) 1.46 (0.70–3.03)
Ethnicity 0.75 0.93
White 1 1
South Asian 0.60 (0.21–1.74) 1.01(0.30–3.38)
Black 0.72 (0.27–1.91) 0.61 (0.14–2.57)
Other 0.72 (0.10–5.32) N/A
Serum creatinine (μmol/L)b 0.99 (0.95–1.03) 0.72 0.97 (0.90–1.03) 0.30
Estimated GFR (mL/min/1.73m2)a 1.00 (0.91–1.09) 0.98 1.18 (1.03–1.36) 0.016
Baseline AKI 1.12 (0.61–2.05) 0.71 0.71 (0.33–1.53) 0.38
Proteinuria
ACR (mg/mmol)c 1.04 (0.93–1.17) 0.51 1.06 (0.94–1.20) 0.34
24 h collection (g/24 h)d 1.25 (0.99–1.59) 0.06 1.01 (0.84–1.21) 0.92
Serum albumin (g/L)e 0.88 (0.69–1.13) 0.32 1.10 (0.83–1.46) 0.50
Serum cholesterol (mmol/L)d 1.02 (0.95–1.11) 0.53 1.02 (0.92–1.14) 0.65
Haematuria 0.79 (0.24–2.62) 0.70 0.33 (0.04–2.47) 0.28
Steroid resistance 1.45 (0.44–4.80) 0.54
Time to remission (weeks)d 0.99 (0.96–1.02) 0.68
Duration of initial course of prednisolonef 0.88 (0.72–1.06) 0.18
HR hazard ratio; CI confidence interval; GFR glomerular filtration rate; AKI acute kidney injury; ACR albumin-to-creatinine ratio. aper 10 units; bper 20 units; cper
100 units; dper 1 unit; eper 5 units; fper 1 month of therapy, analysed after excluding those who relapsed while still on their initial prednisolone
Fig. 2 Kaplan-Meier plot showing the cumulative proportion of the
cohort who relapsed from the time of attaining complete remission
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the 11 steroid-dependent patients, five were treated with
a CNI in addition to prednisolone.
Of the patients initially designated steroid-resistant,
both patients who achieved CR after cyclophosphamide
treatment went on to relapse: one was given a CNI in
addition to high-dose prednisolone and attained remis-
sion, and the other was given high-dose prednisolone
but died before remission was achieved (cause of death
unavailable). Of the two patients who achieved CR after
a CNI, one relapsed but re-entered remission with
high-dose prednisolone.
The associations between baseline patient characteris-
tics and risk of relapse are presented in Table 2. A higher
eGFR was associated with a significantly increased risk
of relapse (HR 1.18 [1.03–1.36] per 10 mL/min increase
in eGFR, P = 0.016). This association between baseline
kidney function and relapse was borne out when re-
lapsers were compared to non-relapsers; relapsers had a
lower baseline creatinine (93 vs 119 μmol/L, P = 0.019)
and higher eGFR (85 vs 57 mL/min, P = 0.015).
To analyse the association between baseline character-
istics and time to relapse further, early relapsers (<
6 months, 17 patients), late relapsers (> 6 months, 12 pa-
tients), and non-relapsers (20 patients) were compared.
Females were significantly more likely than males to ex-
perience an early relapse (57% vs 18%, P = 0.006). There
was no significant association with age, ethnicity, eGFR,
serum albumin, level of proteinuria, the presence of
haematuria, AKI at presentation, steroid-resistance, time
to CR, or duration of initial prednisolone therapy.
Therapeutic agents
Seventy-six (97%) patients were treated with prednisol-
one at some point during follow-up. Patients received a
median of two courses (IQR 1–3, range 0–7), and had a
median total prednisolone exposure of 76 (IQR 32–168)
weeks during follow-up.
The proportion of the whole cohort (N = 78) treated
with second-line immunosuppressants are shown in
Table 3. Thirty-three (42%) patients required at least one
additional agent at some point during follow-up. Cal-
cineurin inhibitors were the most common additional
agent used, being used in 25 (32%) patients (15 received
ciclosporin and 10 received tacrolimus), in whom the
median total duration of CNI exposure was 35 (IQR 16–
45) months. They were used in three patients for
steroid-resistance (two of whom achieved CR), and in 22
for relapsing disease (18 of whom achieved remission, al-
though 15 of these went on to relapse again).
Oral cyclophosphamide was used in 10 (13%) patients,
for a median duration of 10 (IQR 7–13) weeks. It had
been used in two patients for steroid-resistance (both
achieved remission but went on to relapse), and in eight
for relapsing disease (seven achieved CR, four of whom
relapsed again). Rituximab was used in four patients for
relapsing disease, all of whom achieved CR, and none
went on to relapse during follow-up. Other agents used
for relapsing disease included levamisole in seven (9%)
and mycophenolate mofetil in six (8%) patients.
Forty-nine (63%) patients were treated with a
renin-angiotensin system (RAS) inhibitor at some point
during follow-up.
Subsequent renal biopsies and FSGS
Sixteen patients had subsequent renal biopsies, all of
whom had received a CNI. Seven of these had evidence
of CNI damage, and five showed FSGS.
Those who were subsequently diagnosed with FSGS
(N = 5) had a significantly lower baseline serum creatin-
ine (58 vs 109 μmol/L, P = 0.028) and higher serum al-
bumin (27 vs 20 g/L, P = 0.047). Patients with FSGS had
a longer time to remission (43 vs 4 weeks, P = 0.039) and
were more likely to be steroid resistant (60% vs 9%, P =
0.014). There were no significant differences in those
who subsequently developed FSGS with regards to age,
gender, ethnicity, level of proteinuria, the presence of
haematuria, or AKI at presentation.
Outcomes
At last follow-up, median serum creatinine was 87 (68–
108) μmol/L, median eGFR was 78 (59–104) mL/min,
and one patient had renal failure requiring haemodialysis
(this patient had a relapse which precipitated
dialysis-requiring AKI, which failed to recover before
Table 3 Use of second-line immunosuppressants
Immunosuppressant N (%) of cohort treated Duration of therapy Achieved CR (N) Relapsed (N) Time to relapse (months)
Calcineurin inhibitors 25 (32) 18 (10–34)a 21 16 7 (2–22)
Cyclophosphamide 10 (13) 9 (8–10)b 9 6 20 (5–44)
Levamisole 7 (9) 7 (4–38)b 6 5 10 (3–14)
Mycophenolate mofetil 6 (8) 10 (3–29)a 4 3 47 (25–56)
Rituximab 4 (5) N/A 4 0 N/A
The table shows the number (percentage) of the total cohort treated with each class of immunosuppressant, with the median (IQR) duration of the course, and
the number who achieved complete remission. The number who went on to relapse is shown, with the median (IQR) time to relapse. Cyclophosphamide was
given orally in all cases. If a patient received more than one course of a particular class of agent, the median therapy duration of therapy and the remission/
relapse rates relate to the first course given. amonths; bweeks
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death six weeks later). A higher follow-up creatinine was
found in those who were in AKI at presentation (91 vs
82 μmol/L, P = 0.050), and in those who had been com-
menced on a RAS inhibitor at some point after their
renal biopsy (94 vs 78 μmol/L, P = 0.029). There was no
significant association between follow-up creatinine and
the presence of haematuria, being steroid-resistant, hav-
ing one or more relapses, or a diagnosis of FSGS.
Twenty-seven (35%) patients had at least one hospital
admission during follow-up. Thirty-two (41%) patients
had an episode of AKI, either at presentation or during
follow-up, including 12 (15%) patients who had an epi-
sode of stage 3 AKI. Although more patients treated
with a RAS inhibitor developed an episode of AKI com-
pared to those not on a RAS inhibitor, this difference
was not statistically significant (24% vs 17%, P = 0.57).
Other disease and therapy-related complications in-
cluded 11 (14%) who had an admission-requiring infec-
tion, and 9 (12%) who developed diabetes mellitus - of
these, one required treatment with insulin, six required
oral agents, and two were diet-controlled. Six (8%) pa-
tients died during follow-up, at a median age of 84 years
(range 79–85).
Nine (12%) patients developed a venous thrombo-
embolism (VTE). Seven of these were nephrotic at the
time of VTE, and none were on prophylactic anticoagu-
lation at the time. There was no unit protocol for
prophylactic anticoagulation below a specific cut-off of
serum albumin in patients with MCD, but six (8%) pa-
tients had received prophylactic anticoagulation during
episodes of NS, none of whom developed a VTE.
Discussion
There is a paucity of data available on the presenting
features, treatments, and prognosis of MCD in adults,
and so we retrospectively collected data to describe a co-
hort of 78 adults with MCD managed in our renal
centre.
On presentation with the NS, AKI is common: 37% of
our cohort had AKI at first presentation, a similar pro-
portion to that reported in other studies [6, 13, 16].
These patients were significantly older (it is known that
older age is a risk factor for AKI), had more severe
hypoalbuminaemia (which may be associated with intra-
vascular depletion), and had a significantly higher serum
creatinine at last follow-up, findings all consistent with
previous data [9, 12]. Ten per cent of our cohort also
had microscopic haematuria at presentation, which has
previously been reported to be present in approximately
20% in paediatric and adult cohorts [6, 11, 12, 16, 17].
Ninety per cent of newly diagnosed MCD patients
were steroid-responsive, and nearly all patients achieved
remission with immunosuppressive therapy. Median
time to remission was five weeks, which was similar to
that reported in other cohorts [6, 7, 13, 16]. There were
no baseline characteristics significantly associated with
time to remission. It is notable that our rate of steroid
resistance is not higher than that reported in other co-
horts. Current KDIGO guidelines for adult MCD
propose treating for up to 16 weeks with high-dose
glucocorticoid treatment before considering patients to
be steroid-resistant but the strength of the evidence for
this recommendation is low (level 2C) and it is based on
a comparatively small number of adult patients in obser-
vational studies. Clinicians at our centre have generally
taken the view that extended high-dose steroid treat-
ment presents an unacceptable risk of inducing signifi-
cant complications and have therefore tended to opt for
steroid weaning and introduction of additional immuno-
suppressant agents at an earlier time point. Accordingly,
we employed a pragmatic definition of steroid resistance
in our cohort based on clinician decision to change
treatment rather than using the KDIGO definition.
Despite the vast majority of patients achieving remis-
sion, relapse was common, occurring in 61% of the co-
hort, with a median time to relapse of 11 months. The
risk of relapse was increased in those with a higher base-
line eGFR, and there was a significantly increased risk of
early relapse in females. These associations have not
been found in other MCD cohorts, including a recent
study which looked specifically at predictors of relapse
in adult MCD [18]. There is evidence from other MCD
cohorts that younger age is associated with an increased
rate of relapse, but we did not observe this association
in our cohort [6–8, 16, 18]. Duration of initial prednisol-
one treatment and rate of tapering might impact on re-
lapse risk and slow tapering is proposed in KDIGO
guidelines on this basis. At our centre, prednisolone
treatment duration and tapering were determined by the
treating clinician rather than by protocol. Initial prednis-
olone therapy (in a tapering regimen) was continued for
a median of 6 (IQR 4–12) months indicating that most
patients were not treated with shorter course steroids
but notably we found no significant association between
the total duration of initial prednisolone therapy and risk
of relapse.
Nearly half of the total cohort received at least one im-
munosuppressant in addition to prednisolone. Calcine-
urin inhibitors were the most common agents used: a
third of our cohort received one at some point, and the
majority achieved remission. In this context, serious in-
fection and new onset diabetes mellitus still developed
at comparatively high rates (14% and 12%, respectively).
Whilst all immunosuppressant agents can potentially in-
duce significant side-effects, we would argue that it is
unlikely that more extended high dose steroid treatment
before introducing other agents represents the optimal
approach for managing adult MCD.
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There is also a growing body of evidence demonstrat-
ing the effectiveness of rituximab in adults with relaps-
ing MCD [19–23]; four patients in our cohort were
treated with rituximab, and all achieved sustained remis-
sion with no relapses during follow-up. Since the time of
data collection, more patients with relapsing MCD in
our centre have successfully been treated with rituximab
which we have reported elsewhere [24]. We believe that
further research to determine the utility of rituximab as
a means to reduce dependence on high-dose steroid and
other immunosuppressant agents in adult MCD would
be of considerable value.
Two-thirds of our cohort were commenced on a RAS
inhibitor at some point after their diagnosis of MCD,
and their use was associated with a significantly higher
follow-up serum creatinine. Although RAS inhibitors are
often used in proteinuric kidney disease, there is no ra-
tionale for the use of RAS inhibitors in cases of MCD
where the proteinuria resolves quickly with immunosup-
pression. RAS inhibitors may increase the risk of AKI
which is already common in MCD especially during
nephrotic episodes. Although there was no significant
difference in the number of patients who developed AKI
between those treated with a RAS inhibitor and those
not treated, we did not have data on whether patients
were on the RAS inhibitors during relapses when pa-
tients would be at the highest risk of AKI.
Renal function was well-preserved at the end of
follow-up, and only one patient was requiring dialysis at
last follow-up, consistent with other published data. Five
patients were diagnosed with FSGS, and as expected
these patients were more likely to be steroid resistant
and had a significantly longer time to CR. Interestingly,
neither more severe hypoalbuminaemia nor higher
serum creatinine at the time of presentation were indica-
tors of a higher risk of FSGS.
This study is one of the larger cohorts of adult MCD
patients published to date, but we recognise that it has
limitations. The data were retrospectively collected and
were, therefore, dependent upon the accuracy and com-
pleteness of hospital databases and clinic letters. The
data were neither created nor collected to answer a spe-
cific hypothesis, but have been used to provide an over-
view of the adult MCD cohort in our centre.
Conclusions
Nearly all adults with MCD achieve remission, but re-
lapses and disease-related complications are common.
Several characteristics associated with risk of relapse in
our cohort have not been described previously and could
be explored further in future work. Patients commonly
require extra immunosuppression in addition to the
standard treatment of glucocorticoids, and adverse ef-
fects are seen in a significant proportion of patients.
There remains a paucity of evidence to guide the man-
agement of adult MCD. Large, prospective, observational
cohort studies would provide a better understanding of
the natural history and prognosis of adults with MCD,
and there is a real need for RCTs to guide the treatment
of steroid-resistant and frequently relapsing disease, in-
cluding further investigation of the efficacy of rituximab.
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